Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
作者： Marigdalia K. Ramirez-Fort , Emily C. Case , Alyx C. Rosen , Felipe B. Cerci , Shenhong Wu
DOI: 10.1097/COC.0B013E318277D62F
关键词:
摘要: Background:Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for treatment renal cell carcinoma, subependymal giant astrocytoma, breast cancer, and progressive neuroendocrine tumors pancreatic origin. Its use may be hindered because adverse events, including rash.
researchgate.net 
sci-hub.se 参考文章(36)
Sébastien Albert, Maria Serova, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre, Eric Raymond, New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opinion on Investigational Drugs. ,vol. 19, pp. 919- 930 ,(2010) , 10.1517/13543784.2010.499121
Scott A. Soefje, Anand Karnad, Andrew J. Brenner, Common toxicities of mammalian target of rapamycin inhibitors. Targeted Oncology. ,vol. 6, pp. 125- 129 ,(2011) , 10.1007/S11523-011-0174-9
Brian M. Slomovitz, Karen H. Lu, Taren Johnston, Robert L. Coleman, Mark Munsell, Russell R. Broaddus, Cheryl Walker, Lois M. Ramondetta, Thomas W. Burke, David M. Gershenson, Judith Wolf, A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer. ,vol. 116, pp. 5415- 5419 ,(2010) , 10.1002/CNCR.25515
Diane C Fingar, John Blenis, Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene. ,vol. 23, pp. 3151- 3171 ,(2004) , 10.1038/SJ.ONC.1207542
Christopher G. Proud, The multifaceted role of mTOR in cellular stress responses. DNA Repair. ,vol. 3, pp. 927- 934 ,(2004) , 10.1016/J.DNAREP.2004.03.012
Mario E. Lacouture, Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer. ,vol. 6, pp. 803- 812 ,(2006) , 10.1038/NRC1970
Robert J. Amato, Jaroslaw Jac, Sarah Giessinger, Somyata Saxena, James P. Willis, A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer Cancer. ,vol. 115, pp. 2438- 2446 ,(2009) , 10.1002/CNCR.24280
Mona Gandhi, Timothy Kuzel, Mario Lacouture, Eosinophilic rash secondary to temsirolimus. Clinical Genitourinary Cancer. ,vol. 7, ,(2009) , 10.3816/CGC.2009.N.019
Walter Schuler, Richard Sedrani, Sylvain Cottens, Barbara H??berlin, Manfred Schulz, Henk-Jan Schuurman, Gerhard Zenke, Hans-G??nter Zerwes, Max H. Schreier, SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo Transplantation. ,vol. 64, pp. 36- 42 ,(1997) , 10.1097/00007890-199707150-00008
Tianhong Li, Roman Perez-Soler, Skin toxicities associated with epidermal growth factor receptor inhibitors Targeted Oncology. ,vol. 4, pp. 107- 119 ,(2009) , 10.1007/S11523-009-0114-0